BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 37164978)

  • 21. LPAR1 and aberrantly expressed LPAR3 differentially promote the migration and proliferation of malignant peripheral nerve sheath tumor cells.
    Doutt SW; Longo JF; Carroll SL
    Glia; 2023 Mar; 71(3):742-757. PubMed ID: 36416236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of Polycomb Repressive Complex in Malignant Peripheral Nerve Sheath Tumor.
    Zhang X; Murray B; Mo G; Shern JF
    Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32182803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methylation-based classification of benign and malignant peripheral nerve sheath tumors.
    Röhrich M; Koelsche C; Schrimpf D; Capper D; Sahm F; Kratz A; Reuss J; Hovestadt V; Jones DT; Bewerunge-Hudler M; Becker A; Weis J; Mawrin C; Mittelbronn M; Perry A; Mautner VF; Mechtersheimer G; Hartmann C; Okuducu AF; Arp M; Seiz-Rosenhagen M; Hänggi D; Heim S; Paulus W; Schittenhelm J; Ahmadi R; Herold-Mende C; Unterberg A; Pfister SM; von Deimling A; Reuss DE
    Acta Neuropathol; 2016 Jun; 131(6):877-87. PubMed ID: 26857854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.
    Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J
    Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating tumor DNA for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
    Jones J; Cain S; Pesic-Smith J; Choong PFM; Morokoff AP; Drummond KJ; Dabscheck G
    J Neurooncol; 2021 Sep; 154(3):265-274. PubMed ID: 34529228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FOXM1 promotes neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor progression in a NUF2-dependent manner.
    Aimaier R; Chung MH; Gu Y; Yu Q; Wei C; Li H; Guo Z; Long M; Li Y; Wang W; Li Q; Wang Z
    Cancer Gene Ther; 2023 Oct; 30(10):1390-1402. PubMed ID: 37488294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
    Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient-derived orthotopic xenografts, cell lines and tumor entities.
    Creus-Bachiller E; Fernández-Rodríguez J; Magallón-Lorenz M; Ortega-Bertran S; Navas-Rutete S; Romagosa C; Silva TM; Pané M; Estival A; Perez Sidelnikova D; Morell M; Mazuelas H; Carrió M; Lausová T; Reuss D; Gel B; Villanueva A; Serra E; Lázaro C
    Mol Oncol; 2024 Apr; 18(4):895-917. PubMed ID: 37798904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
    Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.
    Borcherding DC; Amin NV; He K; Zhang X; Lyu Y; Dehner C; Bhatia H; Gothra A; Daud L; Ruminski P; Pratilas CA; Pollard K; Sundby T; Widemann BC; Hirbe AC
    Clin Cancer Res; 2023 Apr; 29(8):1592-1604. PubMed ID: 36799629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings.
    Spurlock G; Knight SJ; Thomas N; Kiehl TR; Guha A; Upadhyaya M
    J Cancer Res Clin Oncol; 2010 Dec; 136(12):1869-80. PubMed ID: 20229272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis.
    González-Muñoz T; Di Giannatale A; García-Silva S; Santos V; Sánchez-Redondo S; Savini C; Graña-Castro O; Blanco-Aparicio C; Fischer S; De Wever O; Creus-Bachiller E; Ortega-Bertran S; Pisapia DJ; Rodríguez-Peralto JL; Fernández-Rodríguez J; Pérez-Portabella CR; Alaggio R; Benassi MS; Pazzaglia L; Scotlandi K; Ratner N; Yohay K; Theuer CP; Peinado H
    Clin Cancer Res; 2023 Sep; 29(18):3744-3758. PubMed ID: 37432984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Malignant peripheral nerve sheath tumor in children: A clinicopathologic and molecular study with parallels to the adult counterpart.
    Agaram NP; Wexler LH; Chi P; Antonescu CR
    Genes Chromosomes Cancer; 2023 Mar; 62(3):131-138. PubMed ID: 36414547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors.
    Ghadimi MP; Young ED; Belousov R; Zhang Y; Lopez G; Lusby K; Kivlin C; Demicco EG; Creighton CJ; Lazar AJ; Pollock RE; Lev D
    Clin Cancer Res; 2012 May; 18(9):2545-57. PubMed ID: 22407831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
    Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
    J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
    Kohlmeyer JL; Kaemmer CA; Pulliam C; Maharjan CK; Samayoa AM; Major HJ; Cornick KE; Knepper-Adrian V; Khanna R; Sieren JC; Leidinger MR; Meyerholz DK; Zamba KD; Weimer JM; Dodd RD; Darbro BW; Tanas MR; Quelle DE
    Clin Cancer Res; 2020 Jun; 26(12):2997-3011. PubMed ID: 32086342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors: II. The role of dysregulated growth factor signaling.
    Carroll SL; Stonecypher MS
    J Neuropathol Exp Neurol; 2005 Jan; 64(1):1-9. PubMed ID: 15715079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
    Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
    Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. VEGF and VEGFR family members are expressed by neoplastic cells of NF1-associated tumors and may play an oncogenic role in malignant peripheral nerve sheath tumor growth through an autocrine loop.
    Bonsang B; Maksimovic L; Maille P; Martin N; Laurendeau I; Pasmant E; Bièche I; Deschamps J; Wolkenstein P; Ortonne N
    Ann Diagn Pathol; 2022 Oct; 60():151997. PubMed ID: 35777330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.
    Wu LMN; Zhang F; Rao R; Adam M; Pollard K; Szabo S; Liu X; Belcher KA; Luo Z; Ogurek S; Reilly C; Zhou X; Zhang L; Rubin J; Chang LS; Xin M; Yu J; Suva M; Pratilas CA; Potter S; Lu QR
    Sci Adv; 2022 Nov; 8(44):eabo5442. PubMed ID: 36322658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.